Rhumbline Advisers Keros Therapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 40,476 shares of KROS stock, worth $2.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,476
Previous 41,638 2.79%
Holding current value
$2.32 Million
Previous $1.9 Million 23.55%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$41.68 - $58.07 $48,432 - $67,477
-1,162 Reduced 2.79%
40,476 $2.35 Million
Q2 2024

Aug 01, 2024
BUY
$44.58 - $66.89 $317,008 - $475,654
7,111 Added 20.6%
41,638 $1.9 Million
Q1 2024

May 09, 2024
BUY
$41.26 - $70.48 $118,416 - $202,277
2,870 Added 9.07%
34,527 $2.29 Million
Q4 2023

Feb 08, 2024
SELL
$27.12 - $41.05 $24,028 - $36,370
-886 Reduced 2.72%
31,657 $1.26 Million
Q3 2023

Nov 09, 2023
SELL
$31.57 - $43.02 $12,943 - $17,638
-410 Reduced 1.24%
32,543 $1.04 Million
Q2 2023

Aug 08, 2023
BUY
$37.26 - $51.01 $181,158 - $248,010
4,862 Added 17.31%
32,953 $1.32 Million
Q1 2023

May 11, 2023
BUY
$41.44 - $59.32 $70,738 - $101,259
1,707 Added 6.47%
28,091 $1.2 Million
Q4 2022

Feb 14, 2023
BUY
$39.45 - $51.77 $119,415 - $156,707
3,027 Added 12.96%
26,384 $1.27 Million
Q3 2022

Nov 10, 2022
BUY
$27.8 - $40.12 $86,346 - $124,612
3,106 Added 15.34%
23,357 $879,000
Q2 2022

Aug 11, 2022
BUY
$26.03 - $67.04 $113,620 - $292,629
4,365 Added 27.48%
20,251 $560,000
Q1 2022

May 12, 2022
BUY
$42.12 - $59.36 $83,566 - $117,770
1,984 Added 14.27%
15,886 $864,000
Q4 2021

Feb 10, 2022
SELL
$36.95 - $62.89 $10,456 - $17,797
-283 Reduced 2.0%
13,902 $813,000
Q3 2021

Nov 12, 2021
BUY
$29.27 - $43.71 $19,903 - $29,722
680 Added 5.04%
14,185 $561,000
Q2 2021

Aug 05, 2021
SELL
$42.4 - $70.11 $7,208 - $11,918
-170 Reduced 1.24%
13,505 $574,000
Q1 2021

May 06, 2021
BUY
$54.0 - $75.28 $3,456 - $4,817
64 Added 0.47%
13,675 $842,000
Q4 2020

Feb 10, 2021
BUY
$36.0 - $82.74 $237,168 - $545,091
6,588 Added 93.81%
13,611 $960,000
Q3 2020

Nov 12, 2020
SELL
$27.04 - $62.21 $21,929 - $50,452
-811 Reduced 10.35%
7,023 $271,000
Q2 2020

Aug 13, 2020
BUY
$20.08 - $40.39 $157,306 - $316,415
7,834 New
7,834 $294,000

Others Institutions Holding KROS

# of Institutions
174
Shares Held
30.3M
Call Options Held
76.8K
Put Options Held
9K
View Full List

About Keros Therapeutics, Inc.

KROS Quotes by TradingView
  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.48B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email